Minocycline in Huntington's disease: A pilot study

Madhavi Thomas, Tetsuo Ashizawa, Joseph Jankovic

Research output: Contribution to journalArticlepeer-review

100 Scopus citations


Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase (iNOS), and has been shown to delay disease progression in the mouse model R6/2 of Huntington's disease (HD). This safety and tolerability study included 30 patients with HD who were given minocycline over a 6-month period and underwent assessments every 2 months with laboratory studies, the Abnormal Involuntary Movements Scale, the Unified Huntington's Disease Rating Scale, and the Mini-Mental State Examination. Minocycline was well tolerated during this study period and no serious adverse events were noted.

Original languageEnglish (US)
Pages (from-to)692-695
Number of pages4
JournalMovement Disorders
Issue number6
StatePublished - Jun 2004


  • Apoptosis
  • Caspase inhibition
  • Huntington's disease
  • Minocycline
  • Neuroprotection

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Minocycline in Huntington's disease: A pilot study'. Together they form a unique fingerprint.

Cite this